RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications
Nucleic Acids Research · 06.01.2023 · 51 (D1) · D269-D279
DOI: 10.1093/nar/gkac945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 27.10.2022. Verfasst von Xiaoqiong Bao und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat…. Hauptthemen laut MEDLINE: RNA Processing, Post-Transcriptional, Databases, Nucleic Acid. Die Arbeit wurde bisher 93-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Guangdong Basic and Applied Basic Research Foundation, Program for Guangdong Introducing Innovative and Entrepreneurial Teams.
Abstract (Originalsprache)
RNA modification is a dynamic and reversible process regulated by a series of writers, erasers and readers (WERs). Abnormal changes of WERs will disrupt the RNA modification homeostasis of their target genes, leading to the dysregulation of RNA metabolisms such as RNA stability and translation, and consequently to diseases such as cancer. A public repository hosting the regulatory relationships between WERs and their target genes will help in understanding the roles of RNA modifications in various physiological and pathological conditions. Previously, we developed a database named ‘m6A2Target’ to host targets of WERs in m6A, one of the most prevalent RNA modifications in eukaryotic cells. To host all RNA modification (RM)-related WER–target associations, we hereby present an updated database, named ‘RM2Target’ (http://rm2target.canceromics.org/). In this update, RM2Target encompasses 1 619 653 WER–target associations for nine RNA modifications in human and mouse, including m6A, m6Am, m5C, m5U, m1A, m7G, pseudouridine, 2′-O-Me and A-to-I. Extensive annotations of target genes are available in RM2Target, including but not limited to basic gene information, RNA modifications, RNA–RNA/RNA–protein interactions and related diseases. Altogether, we expect that RM2Target will facilitate further downstream functional and mechanistic studies in the field of RNA modification research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Cancer Center, Collaborative Innovation Center for Cancer Medicine, School of Life Sciences, Sun Yat-sen University, Guangzhou 510060, China.
- Experimental Research Center, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou 310016, China.
ORCID-Profile: Jian Zheng, Jian Ren, Zhixiang Zuo
Förderung
- National Key Research and Development Program of China
- Guangdong Basic and Applied Basic Research Foundation
- Program for Guangdong Introducing Innovative and Entrepreneurial Teams
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Bao, X., Zhang, Y., Li, H., Teng, Y., Ma, L., Chen, Z., Luo, X., Zheng, J., Zhao, A., Ren, J., & Zuo, Z. (2023). RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications. Nucleic Acids Research, 51(D1), D269-D279. https://doi.org/10.1093/nar/gkac945
Vancouver
Bao X, Zhang Y, Li H, Teng Y, Ma L, Chen Z, et al. RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications. Nucleic Acids Research. 2023;51(D1):D269-D279. doi:10.1093/nar/gkac945
BibTeX
@article{Bao2023,
author = {Bao, Xiaoqiong and Zhang, Yin and Li, Huiqin and Teng, Yuyan and Ma, Lixia and Chen, Zhihang and Luo, Xiaotong and Zheng, Jian and Zhao, An and Ren, Jian and Zuo, Zhixiang},
title = {RM2Target: a comprehensive database for targets of writers, erasers and readers of RNA modifications},
journal = {Nucleic Acids Research},
year = {2023},
volume = {51},
number = {D1},
pages = {D269--D279},
doi = {10.1093/nar/gkac945}
}
EUVIMED